BCAX Bicara Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2023658 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-81.3%
TTM EPS YoY-164.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-54.2%
ROA-49.8%
ROIC (approx.)-67.1%
Asset turnover—
Leverage & solvency
Liabilities / assets11.1%
Debt / equity0.00x
Current ratio8.81x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-13.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | — | — | — | — | $33.00M | $24.80M | $34.30M | $19.90M |
| SG&A expense | $19.23M | $14.18M | $12.74M | $8.13M | $7.70M | $7.22M | $7.46M | $6.75M |
| Operating income | -$75.71M | -$59.95M | -$60.24M | -$41.12M | -$40.68M | -$32.02M | -$41.79M | -$26.64M |
| Pretax income | -$71.19M | -$55.38M | -$56.16M | -$37.33M | -$36.29M | -$27.34M | -$36.77M | -$20.77M |
| Income tax | $54,000 | $61,000 | $52,000 | $53,000 | $40,000 | $52,000 | $72,000 | $179,000 |
| Net income | -$71.25M | -$55.44M | -$56.21M | -$37.39M | -$36.33M | -$27.39M | -$36.85M | -$20.96M |
| EBITDA | -$75.65M | -$59.91M | -$60.20M | -$41.08M | -$40.65M | -$32.00M | -$41.77M | -$26.62M |
| EPS (basic) | -1.04 | -0.82 | -0.93 | — | -0.67 | -0.50 | -0.68 | — |
| EPS (diluted) | -1.04 | -0.82 | -0.93 | — | -0.67 | -0.50 | -0.68 | — |
| Weighted avg. shares (diluted) | 68.38M | 67.93M | 60.72M | — | 54.56M | 54.54M | 54.46M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $82.02M | $96.60M | $323.46M | $96.69M | $171.67M | $436.61M | $462.06M | $489.71M |
| Short-term investments | $360.32M | $400.66M | $216.29M | $318.12M | $118.49M | — | — | $0 |
| Current assets | $451.41M | $503.82M | $544.91M | $422.05M | $297.37M | $444.39M | $470.75M | $502.53M |
| PP&E, net | $965,000 | $362,000 | $346,000 | $330,000 | $135,000 | $117,000 | $136,000 | $155,000 |
| Total assets | $460.64M | $512.24M | $553.60M | $430.99M | $424.69M | $453.59M | $478.08M | $510.00M |
| Current liabilities | $51.23M | $43.48M | $39.34M | $28.95M | $21.03M | $17.23M | $19.12M | $17.99M |
| Total liabilities | $51.23M | $43.48M | $39.64M | $29.54M | $21.91M | $18.39M | $19.12M | $18.12M |
| Shareholders' equity | $409.41M | $468.77M | $513.96M | $401.45M | $402.78M | $435.20M | $458.96M | $491.88M |
| Shares outstanding | 66.35M | 65.93M | 65.55M | 56.60M | 54.61M | 54.56M | 54.53M | 54.44M |
| Cash flow statement | ||||||||
| Operating cash flow | -$56.13M | -$44.21M | -$37.51M | -$23.89M | -$29.25M | -$25.59M | -$28.11M | -$30.03M |
| Capital expenditure | $663,000 | $60,000 | $60,000 | $238,000 | $42,000 | $0 | $0 | $40,000 |
| Free cash flow | -$56.79M | -$44.27M | -$37.57M | -$24.12M | -$29.29M | -$25.59M | -$28.11M | -$30.07M |
| Investing cash flow | $38.34M | -$184.99M | $100.94M | -$82.33M | -$236.12M | $0 | $0 | -$40,000 |
| Financing cash flow | $3.21M | $2.33M | $163.34M | $31.23M | $436,000 | $135,000 | $460,000 | -$975,000 |
| Depreciation & amortization | $60,000 | $44,000 | $44,000 | $43,000 | $24,000 | $19,000 | $19,000 | $15,000 |
| Stock-based compensation | $9.98M | $8.24M | $5.86M | $4.45M | $3.61M | $3.49M | $3.45M | $3.18M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.